Neuraxis, INC

Neuraxis, Inc. reported a significant increase in net sales for the second quarter of 2026, reaching $1.93 million, a 115.7% rise year-over-year. Despite this revenue growth, the company continues to incur net losses, with a net loss of $2.09 million for the quarter and $3.85 million for the six months ended June 30, 2026. The company's financial statements include a "going concern" warning, indicating substantial doubt about its ability to continue operations without additional funding, despite an improved cash position and working capital surplus.

NeurAxis, Inc. reported strong second quarter 2026 results, with revenue increasing 116% year-over-year to $1.9 million, driven by the effective Category I CPT code for PENFS. Gross margin expanded to 85.9%, and cash used in operations decreased. The company also achieved significant operational milestones, including securing a VA Federal Supply Schedule contract and expanding FDA clearance for its IB-Stim technology, positioning it for continued growth and broader insurance coverage.

Neuraxis, Inc. announced additional medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, expanding access to over 500,000 covered lives in the Mid-Atlantic region. CEO Brian Carrico highlighted the progress with major payers, strengthening the reimbursement network, and building momentum towards comprehensive nationwide coverage. IB-Stim is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia in patients aged 8 and older, addressing a significant unmet medical need.

NeurAxis, Inc. announced it will report its summarized financial results for the second quarter ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The company will host a conference call on the same day at 9:00 am ET to discuss the results. Details for the conference call, including dial-in numbers and webcast link, were provided.

Neuraxis, Inc. announced that its Board of Directors authorized and declared a stock dividend for the second quarter of 2026 on its Series B Preferred Stock. This dividend will be paid in shares of the Company's common stock, with approximately 80,463 common shares expected to be issued. The dividend is payable on July 29, 2026, to shareholders of record as of July 21, 2026.

Neuraxis reported a significant increase in net sales for Q1 2026, rising 79.5% to $1.61 million, with gross profit up 83.7% to $1.39 million. The company reduced its net loss to $(1.76) million from $(2.28) million in the prior year, and loss per share improved to $(0.18). Cash and stockholders' equity saw substantial growth due to financing activities, though the company continues to operate at a loss and has a going concern warning.

Neuraxis reported strong first quarter 2026 financial results, with revenue increasing 80% year-over-year to $1.6 million and operating loss improving by 24%. This performance was primarily driven by the effective AMA Category I CPT® code for Percutaneous Electrical Nerve Field Stimulation (PENFS), which substantially increased payor coverage and allowed more IB-Stim® devices to be sold at full price, expanding gross margin by 200 basis points. The company also achieved significant operational milestones, including securing a Veterans Affairs Federal Supply Schedule contract and receiving the first-ever FDA clearance for abdominal pain in functional dyspepsia with associated nausea symptoms, expanding the total addressable market for IB-Stim.

NeurAxis, Inc. announced it will report its summarized financial results for the first quarter ended March 31, 2026, on Tuesday, May 12, 2026, before market open. The medical technology company has also scheduled a conference call for the same day at 9:00 am ET to discuss the results, with details provided for both dial-in and webcast access.

Neuraxis, Inc. announced its Annual Meeting of Stockholders to be held on June 10, 2026, to vote on several key proposals. These include the election of six directors, the ratification of Rosenberg Rich Baker Berman, P.A. as the independent auditor for fiscal year 2026, and the approval of amendments to the 2022 Omnibus Securities and Incentive Plan to increase authorized shares. Additionally, stockholders will vote on the approval of the 2025 Employee Stock Purchase Plan and the authorization to adjourn the meeting if necessary. The record date for voting is April 14, 2026.

Neuraxis, Inc. has increased the aggregate offering price of its At The Market (ATM) offering agreement with Craig-Hallum Capital Group LLC. The company originally entered into the agreement on August 29, 2025, to sell up to $6,270,000 in common stock. As of April 20, 2026, Neuraxis had sold 1,125,281 shares under this agreement. On April 21, 2026, the company amended the prospectus supplements to raise the total potential offering amount to $11,500,000.